anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients with liver tumors who underwent US-guided-MWA of liver tumors were enrolled. These patients were allocated into three groups based on tumor size and number: A, B, and C. Prior to the ablation procedure, Group A patients received a combination of hepatic hilar block (HHB), Transversus abdominis plane block (TAPB), and local anesthesia (LA). Patients in Group B were administered HHB in conjunction with LA, while those in Group C received TAPB and LA.Pain levels were routinely assessed through the Numerical Rating Scale (NRS), with scores being recorded by the attending nurse every 15 minutes. The frequency of these assessments would be increased if the patient reported discomfort or if there were changes observed in vital signs. If a patient reported a pain level of ≥4 on the NRS scale, an intravenous dose of 10mg morphine was administered, provided that cardiopulmonary safety could be assured. The determination of cardiopulmonary safety was made by the interventional radiologist (M. L. with 20 years of experience). Following the ablation procedure, all patients were monitored for a period of 36 hours. During this period, several parameters were recorded at the time of the procedure and again at 4, 8-, 12-, 24-, and 36-hours post-procedure. These parameters included the NRS score, vital signs, any need for morphine, and the occurrence of any adverse events.
Degradable magnesium alloy stents are considered to be ideal candidates to replace the traditional non-degradable stents for the treatment of cardiovascular diseases. However, bare magnesium alloy stents usually degrade too fast and show poor hemocompatibility and cytocompatibility, which seriously affects their clinical use. In this study, surface modification based on the MgF2 layer, polydopamine (PDA) coating, fucoidan and CAG peptides was performed on the Mg-Zn-Y-Nd (ZE21B) magnesium alloy with the purpose of improving its corrosion resistance, hemocompatibility and cytocompatibility for vascular stent application. After modification, the ZE21B alloy showed better corrosion resistance. Moreover, the lower hemolysis rate, platelet adhesion and activation, and fibrinogen adsorption and denaturation proved the improved hemocompatibility of modified ZE21B alloy in in vitro blood experiments. Furthermore, the co-immobilization of fucoidan and CAG peptides significantly promoted the adhesion, proliferation, migration and NO release of endothelial cells (ECs) on the modified ZE21B alloy, and meanwhile the modification with fucoidan and CAG peptides inhibited the adhesion and proliferation of smooth muscle cells (SMCs) and suppressed the expression of proinflammatory factors in the macrophages (MAs). The surface modification obviously enhanced the corrosion resistance, hemocompatibility and cytocompatibility of ZE21B alloy, and provided an effective strategy for the development of degradable vascular stents.
The invention discloses a mouth-opening medicine for chickens and a preparation method of the medicine. The mouth-opening medicine consists of the following raw materials in parts by mass: 15-30 parts of scutellaria baicalensis, 10-18 parts of angelica sinensis, 10-20 parts of atractylodes macrocephala koidz and 8-18 parts of radices sileris. The preparation method for the mouth-opening medicine comprises the following steps of mixing the raw materials according to proportions, slicing the raw materials, decocting the medicine for mouth-opening drinking of the just entered chickens; a dosage is decocted and continuously fed to the chickens for three times every day. The scutellaria baicalensis is used for clearing the heat, eliminating the dampness and purging fire to remove the toxin; the angelica sinensis is used for enriching the blood and invigorating the circulation of the blood; the atractylodes macrocephala koidz is used for invigorating spleen, supplementing qi, eliminating dampness, disinhibiting water, preventing and eliminating rheumatism and relieving exterior syndrome. The raw materials are in compatibility to achieve the effects of clearing heat, implementing detoxication, purging the lung of pathogenic fire and stopping asthma. The mouth-opening medicine is used for mouth-opening drinking of the chickens, so that the immunity and the survival rate of the chicken bodies are improved; the survival rate is improved from 95 percent to 98 percent.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to field of chemical and pharmaceutical industry and deals with technology of obtaining extract, containing a complex of biologically active substances, from natural raw materials. Method of obtaining medical extract from natural organic raw materials with natural moisture content which includes dehydration of raw material, extraction by organic solvents or their mixtures, subsequent distillation of solvent in presence of vegetable oil to obtain an extract containing biologically active substances, as raw material used is sapropel with content of organic substance 50-96 wt %, before dehydration sapropel is frozen at temperature below 0C, extraction is carried out by mixture of ethanol with one-, two- or three-atom (C3-C4)-alcohol with weight ratio of solvents 1:1-20:1, and distillation of solvent is carried out under vacuum. As a monatomic alcohol, propanol-2, butanol-2, butanol-3 and 2-methyl-1-propanol, diatomic alcohol-propane-1,2-diol and propane-1,3-diol, triatomic alcohol-propane-1,2,3-triol are used. ^ EFFECT: method ensures increased output of extract. ^ 2 cl, 16 ex, 1 tbl
The invention discloses a traditional Chinese medicine composition for postoperative care of hemorrhoid and a preparation method thereof. The traditional Chinese medicine composition comprises barnyard grass rood juvenile leaf, root or bark of gluey litse, leaf of Yunnan Machilus, Ilex pernyi Franch, Monochasma savatieri Franch., radix Cudrania cochin chinensis, radix Lucuia intermedia Hutch., Tibet velvetplant, Geophila herbacea, Picris divaricata Vaniot, Eurya distichophylla Hemsl., stem and leaf of Cudrania tricuspidata, Guangye Shuisu, herb of nightshadeleaf ironweed, herb of shortscape fleabane, Lysimachia lobelioides Wall., Viola diffusa Ging. and bark of Kalopanax septemlobus. The preparation method comprises the following steps: according to different properties of the above-mentioned bulk drugs, extracting barnyard grass rood juvenile leaf, root or bark of gluey litse, Ilex pernyi Franch, Eurya distichophylla Hemsl. and bark of Kalopanax septemlobus with an ultrasonic extractor; decocting Monochasma savatieri Franch., radix Cudrania cochin chinensis, radix Lucuia intermedia Hutch., Tibet velvetplant, Geophila herbacea, Picris divaricata Vaniot, stem and leaf of Cudrania tricuspidata, Guangye Shuisu, herb of nightshadeleaf ironweed, herb of shortscape fleabane, Lysimachia lobelioides Wall. and Viola diffusa Ging in a stainless steel traditional Chinese medicine decocting machine and carrying out purification by using membrane separation technology; grinding leaf of Yunnan Machilus into powder and blending the obtained powder with honey; and carrying out mixing, adding adjuvant materials and preparing an ointment. The traditional Chinese medicine composition for postoperative care of hemorrhoid has the advantages of a reasonable formula, substantial curative effect, a short treatment course, fast action and no side effect.
The present invention provides plant salt containing sea salt and bitter gourd powder with a NaCl content of 65-80%. The plant salt containing the sea salt and bitter gourd powder consists of the following raw materials in mass percentages: 1-6% of bitter gourd saponin, 0.5-1% of lupeol, and 0.2-0.5% of beta-carotene. The present invention also provides a method for preparing the plant salt by using a mineralizing and filtering technology. The method includes a refined brine preparation step. The refined brine preparation step includes a filtration step. The filtration step uses a brine mineralization and filtration agent to conduct filtration, and the filtration time is 3-5 times. The brine mineralization and filtration agent consists of the following components in weight percentages: 35-65 parts of chlorella, 3-8 parts of beryl, 5-15 parts of lepidolite, 5-20 parts of medical stones, and 20-25 parts of Fe<3>O<4>. The prepared brine mineralization and filtration agent has a better removal effect of heavy metal ions and has a better treatment effect on treating toothache.
The incidence rates of adverse effects in hypertensive patients were derived from multicenter, controlled clinical trials. Following are the rates of adverse effects for nicardipine hydrochloride capsules (n=1390) and placebo (n=211), respectively, that occurred in 0.4% of patients or more. These represent events considered probably drug-related by the investigator. Where the frequency of adverse effects for nicardipine hydrochloride capsules and placebo is similar, causal relationship is uncertain. The only dose-related effect was pedal edema.

Percent of Patients With Adverse Effects in Controlled Studies   
(Incidence of Discontinuations Shown in Parentheses)
Group III will include cases classified as class I obese, with a body mass index of 30.0-34.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
The present invention relates to a novel class of modified malonate derivatives. The modified malonate compounds can be used to treat cancer. The modified malonate compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the modified malonate derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the modified malonate derivatives in vivo.
Despite increasing application and success of personalized treatment in medical oncology, little progress has been made in personalized surgical cancer therapy. The ARMANI trial presents the first prospective, randomized trial to evaluate effectiveness and safety of molecular-guided resection in patients with colorectal liver metastasis (CRLM). While CRLM might be removed independently of the liver's segmental borders, retrospective data favor anatomic resections in the subgroup of patients with a mutation in the RAS oncogene. Therefore, the ARMANI trial will test the hypothesis, if an anatomic resection (AR) improves long-term outcome vs. a non-anatomical resection (NAR) in patients undergoing surgery for RAS-mutated CRLM. The trial will be carried out among 11 high-volume centers of hepato-biliary surgery in Germany. A total of 220 patients will be enrolled and randomized in a 1:1 ratio to undergo an AR vs. NAR. The primary endpoint is intrahepatic disease-free survival (iDFS). In addition, the study will provide important data on perioperative outcomes and quality of life for both surgical techniques. Given the trend among liver surgeons to aim for parenchymal-sparing operations to preserve liver parenchyma, a positive trial will be practice changing and present the first piece of high-level evidence on benefits of personalized surgical therapy guided by the tumor's mutational profile in patients with CRLM.
Lenalidomide 10 mg/day taken daily orally for 12 months of treatment followed by 6 months washout. The trial will last 18 month in duration.
Patients will not be treated with pembrolizumab and will be treated with normal saline after concurrent chemoradiotherapy. Patients will be treated with up to 12 months (17 cycles) of pembrolizumab until disease progression or recurrence.
BACKGROUND: Low back pain (LBP) is a leading cause of disability worldwide and has posed numerous health and socioeconomic challenges. This study compared whether nonsteroidal anti-inflammatory drugs (NSAIDs) in combination with tramadol, tizanidine or placebo would be the best treatment regime to improve the Roland Morris Disability Questionnaire (RMDQ) scores at 1 week.
METHODS: This was a multi-center, double-blind, randomized, and placebo-controlled trial including adult patients with acute LBP and sciatica in three emergency departments in Hong Kong. Patients were randomized to the receive tramadol 50 mg, tizanidine 2 mg, or placebo every 6 hours for 2 weeks in a 1:1:1 ratio. The RMDQ and other secondary outcomes were measured at baseline, Day 2, 7, 14, 21, and 28. Data were analyzed on an intention to treat basis. Crude and adjusted mean differences in the changes of RMDQ and NRS scores from baseline to Day 7 between tizanidine/tramadol and placebo were determined with 95% confidence intervals.
RESULTS: Two hundred and ninety-one patients were analyzed with the mean age of 47.4 years and 57.7% were male. The primary outcome of mean difference in RMDQs on Day 7 (compared with baseline) was non-significant for tizanidine compared with placebo (adjusted mean difference - 0.56, 95% CI -2.48 to 1.37) and tramadol compared with placebo (adjusted mean difference - 0.85, 95% CI -2.80 to 1.10). Only 23.7% were fully compliant to the treatment allocated. Complier Average Causal Effect analysis also showed no difference in the primary outcome for the tizanidine and tramadol versus placebo.
CONCLUSION: Among patients with acute LBP and sciatica presenting to the ED, adding tramadol or tizanidine to diclofenac did not improve functional recovery.
All taVNS procedures will be conducted using the Spark Biomedical device. Electrodes will be placed on the left auricle and we will use stimulation parameters similar to ongoing taVNS work (25Hz, 500us pulse width) and a duty cycle of 1 minute on, 30 s off, repeated for 30 minutes. The low dose taVNS group will receive up to 3 treatments per day over the course of 3 days (for a total of up to 9 treatments).
The study will evaluate the utility of investigational restaging with 18F-DCFPyL PET/CT following conventional imaging (bone scan, CT thorax, abdomen and pelvis plus multi-parametric pelvic MRI) in detecting the prevalence of metastatic disease among men with biochemical recurrence after radical radiotherapy treatment to the prostate. Men treated with primary radiation with external beam or brachytherapy will be eligible. Eighty (80) eligible consenting patients with biochemical recurrence and potentially suitable for local salvage or targeted ablative therapies will be registered and imaged with conventional imaging (bone scan, CT thorax, abdomen and pelvis plus multi-parametric pelvic MRI) followed by investigational restaging with 18F-DCFPyL PET/CT. Characterizing sites of disease identified by the combination of 18F-DCFPyL PET/CT with conventional imaging versus 18F-DCFPyL PET/CT alone will be used to explore the potential of 18F-DCFPyL PET/CT as a single restaging study in men with biochemical recurrence. While further investigation and treatment after restaging will be at the discretion of the investigator and the patient, the actual treatment/management, treatment outcomes and quality of life will be recorded in an electronic database at 6, 12, 24 and 36 months after re-staging. Such longitudinal analyses of management and outcomes will be useful in characterizing the disease trajectory, response to treatment and quality of life for patients whose recurrent disease is managed based on comprehensive restaging using the combination of conventional imaging and 18F-DCFPyL PET/CT.
Described herein are inventions directed to methods of treating a diastolic cardiac dysfunction and the symptoms thereof in a subject that includes administering an amount of a TRPV2 receptor agonist effective to treat the diastolic cardiac dysfunction. The TRPV2 receptor agonist may be administered in at least one of an injection, orally, or transdermally. The amount of TRPV2 receptor agonist is sufficient to result in an improved performance on quantitative diagnostic criteria. In an embodiment, the TRPV2 receptor agonist is administered over a period of about 8 hours to about 24 hours. The TRPV2 receptor agonist may be used for short term treatments, i.e., less than a week, or it may be administered in a long term manner, i.e., over a period of weeks, months, or even years. Exemplary TRPV2 receptor agonists include probenecid, 2-aminoethoxydiphenyl borate, cannabinol, cannabidiol, and combinations thereof.
Peak digoxin body stores of 8 to 12 mcg/kg should provide therapeutic effect with minimum risk of toxicity in most patients with heart failure and normal sinus rhythm. Because of altered digoxin distribution and elimination, projected peak body stores for patients with renal insufficiency should be conservative (i.e., 6 to 10 mcg/kg) (see PRECAUTIONS).

The loading dose should be administered in several portions, with roughly half the total given as the first dose. Additional fractions of this planned total dose may be given at 6- to 8-hour intervals, with careful assessment of clinical response before each additional dose.

If the patient's clinical response necessitates a change from the calculated loading dose of digoxin, then calculation of the maintenance dose should be based upon the amount actually given.

A single initial dose of 500 to 750 mcg (0.5 to 0.75 mg) of Digoxin Tablets usually produces a detectable effect in 0.5 to 2 hours that becomes maximal in 2 to 6 hours. Additional doses of 125 to 375 mcg (0.125 to 0.375 mg) may be given cautiously at 6- to 8-hour intervals until clinical evidence of an adequate effect is noted. The usual amount of Digoxin Tablets that a 70 kg patient requires to achieve 8 to 12 mcg/kg peak body stores is 750 to 1250 mcg (0.75 to 1.25 mg).

Digoxin Injection is frequently used to achieve rapid digitalization, with conversion to Digoxin Tablets for maintenance therapy. If patients are switched from intravenous to oral digoxin formulations, allowances must be made for differences in bioavailability when calculating maintenance dosages (see Table 1, CLINICAL PHARMACOLOGY).
The stimulator of interferon genes (STING) is a crucial signaling hub in the immune system's antiviral and antimicrobial defense by detecting exogenous and endogenous DNA. The multifaceted functions of STING have been uncovered gradually during past decades, including homeostasis maintenance and overfull immunity or inflammation induction. However, the subcellular regulation of STING and mitochondria is poorly understood. The main functions of STING are outlined in this review. Moreover, we discuss how mitochondria and STING interact through multiple mechanisms, including the release of mitochondrial DNA (mtDNA), modulation of mitochondria-associated membrane (MAM) and mitochondrial dynamics, alterations in mitochondrial metabolism, regulation of reactive oxygen species (ROS) production, and mitochondria-related cell death. Finally, we discuss how STING is crucial to disease development, providing a novel perspective on its role in cellular physiology and pathology.
PURPOSE:To offer a reinforced apatite sintered body and its manufacturing method. CONSTITUTION:The acicular crystalline body of apatite is uniformly dispersed as a reinforcing material in a non-bonding state with the above apatite grains. This apatite sintered body can be obtd. by mixing an acicular apatite material in which Ca/P, i.e., the molar ratio of Ca to P is controlled to >1.60 to <1.67 into apatite powder having high reactivity in which the Ca/P is controlled to 1.50 to 1.60 in such a manner that it is uniformly dispersed, subjecting the mixed body to baking treatment at a low temp. of the dissolving temp. of the apatite material having low reactivity or below under a high pressure condition and bringing the apatite powder having high reactivity into a sintering reaction.
This study will recruit a total of 130 colorectal cancer patients. It is expected to recruit about 300 colorectal cancer patients per year. About 25% of these patients are expected to have a mutation with a target drug. ORR will be compared between the targeted group and the untargeted group. The median ORR is expected to be about 25% for the targeted group and about 5% for the untargeted group. With N=130 colorectal cancer patients, about 33 patients will belong to the targeted group and about 97 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 87% of power. The study on colorectal cancer will take about 6 months for accrual.
Levosert is a LNG-releasing Intrauterine Delivery System (IUS) containing 52 mg of LNG in a cylindrical-shaped reservoir. The reservoir is mounted on the vertical arm of a T-shaped plastic frame and is covered with a release rate controlling membrane.
Gastric cancer, as the second common malignant tumors in china, is marked by its poor prognosis and high recurrent rate. Although R0 resection could be achieved in most advanced gastric cancer(AGC) patients without metastasis, age-standardized 5-years survival rate was no more than 27.4%. Peritoneal metastasis accounts for 50% of the recurrent case and remain to be the most fatal recurrence pattern.

Hyperthermic intraperitoneal perfusion chemotherapy ( HIPEC ), has been proved as one of the most efficient approach against peritoneal carcinomatosis from gastric cancer and recommended in the guideline for gastric cancer published by the health committee of china. However, its role as prophylactic treatment after curative has never been determined. HIPEC works by delivering heat and cytotoxic drug to the cancer cell and is more effective on the tumor with small size. As present study suggest that Peritoneal metastasis is related to lymph node dissection during surgery while opening lymphatic channels and spreading viable cancer cells into the peritoneal cavity, HIPEC might be a reasonable approach to destroy the remaining cancer cells after curative surgery. Thus this research aim to explore the efficacy and safety of combining HIPEC (hyperthermic intraperitoneal perfusion chemotherapy) with post-neoadjuvant chemotherapy D2 resection.
The invention discloses a tadalafil tablet and a preparation method thereof, belonging to the technical field of medicines. The formula of the raw and auxiliary materials comprises the following components: 0.5-10% of tadalafil, 50-85% of filler, 5-10% of adhesive, 1-5% of lubricant and 1-10% of disintegrant. The filler is selected from pregelatinized starch, microcrystalline cellulose, and lactose. The binder is selected from hydroxypropyl cellulose, polyvidone K30. Simultaneously, the invention also discloses a preparation method of the tadalafil tablet, which comprises the steps of uniformly stirring the tadalafil, the filling agent and the disintegrating agent, preparing the adhesive solution for stirring, sieving the uniformly stirred wet material, drying, adding the lubricating agent for uniformly stirring, and finally tabletting by using a tabletting machine. The tadalafil tablet obtained by the invention is quick in dissolution and quick in effect, and the invention provides a preparation method of the tadalafil tablet which is simple in process, quick in dissolution and quick in effect.